• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    You can find the latest happening of our pharmacy
    Follow us on Twitter

      FDA approves Novartis drug for rare disease

      Posted AtBusinessweek.com

      The Food and Drug Administration said Monday it approved Novartis' drug Afinitor to treat some of the tumors caused by a rare genetic disorder called tuberous sclerosis.

      Tuberous sclerosis causes tumors in the brain, eyes, lungs, liver and other organs, leading to learning disabilities, seizures and other problems. The tumors are not cancerous, but the disorder -- which affects 25,000 to 40,000 people in the U.S., according to a Novartis spokeswoman -- can be fatal for patients who develop complications with tumor growth in the brain.

      The agency approved Afinitor for the 6 percent to 9 percent of tuberous sclerosis patients who have benign brain tumors called subependymal giant cell astrocytoma that can't be treated with surgery, the FDA said.

      Afinitor is already approved as a treatment for advanced renal cell carcinoma.

      The FDA approved the new indication based on a 28-patient study in which nine patients experienced a 50 percent reduction in the size of their tumors.

      Afinitor was cleared under the FDA's accelerated approval program, which allows approval of new drugs based on preliminary clinical trial results. Companies are required to conduct additional studies to confirm the benefits of their drugs.

      Nov 03, 2010


      Share this Article!

    Back to top^